"Other prespecified secondary end points included total (first and recurrent) hospitalization for congestive heart failure; the incidence of primary end point events, excluding deaths of undetermined cause from cardiovascular deaths; and changes within and between treatment groups in lipid levels, fasting serum glucose level, hemoglobin A1c level, alkaline phosphatase level, and estimated glomerular filtration rate overall and among the subset with baseline estimated glomerular filtration rate less than 60 mL/min/1.73 m2."

The above is copied from the Methods/Endpoints section of the published JAMA 2020 BETonMACE article. We have yet to see "changes within and between treatment groups in lipid levels, fasting serum glucose level, hemoglobin A1c level, alkaline phosphatase level, and estimated glomerular filtration rate" for the CKD subgroup as more thoroughly described in the 2018 CKD sub-study poster below.

https://www.resverlogix.com/upload/media_element/125/20402f6425eb/2018-05-02-era-edta-poster-2018-kidney-disease-subgroup.pdf

It has been nearly 7 months since the November 2019 AHA and Corporate Update and still no complete sub-study data.

BDAZ